Eisai launches LEQEMBI in India for early Alzheimer’s disease treatment EP News Bureau Aug 3, 2026 Launch follows CDSCO marketing authorisation for disease-modifying therapy indicated for patients with mild cognitive impairment…
Eisai India and Mylan to commercialise teceris EP News Bureau Sep 26, 2019 The second eribulin brand in India, teceris aimed at expanding access to metastatic breast cancer patients in India
